Evidence map›Paper›PMID 31645871›Full record

ArticleIranian journal of child neurology2019

Cost-Effectiveness Analysis of Topiramate versus Phenobarbital in the Treatment of Children with Febrile Seizure.

Hamid Nemati, Hamid Talebianpour, Farhad Lotfi, Nazanin Zahra Sepehri, Khosro Keshavarz

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Iranian journal of child neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Prophylactic drug management for febrile seizures in children.The Cochrane database of systematic reviews · 2021
    Pooled it
  3. Correlation ofFrontiers in pediatrics · 2026
    Article
  4. Article
  5. QALY league table of Iran: a practical method for better resource allocation.Cost effectiveness and resource allocation : C/E · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hamid NematiNeuroscience Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Hamid TalebianpourDepartment of Health Care Management, School of Management and Medical Information, Shiraz University of Medical Science, Shiraz, Iran.
Farhad LotfiHealth Human Resources Research Center, School of Management & Medical Informatics, Shiraz University of Medical Sciences, Shiraz, Iran.
Nazanin Zahra SepehriHealth Human Resources Research Center, School of Management & Medical Informatics, Shiraz University of Medical Sciences, Shiraz, Iran.
Khosro KeshavarzHealth Human Resources Research Center, School of Management & Medical Informatics, Shiraz University of Medical Sciences, Shiraz, Iran.
Shiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesFebrile seizure is common disorder in childhood, with a prevalence of 2% to 5%. There are many drugs for treatment of this disease; however, the most common prescribed medication in Iran is phenobarbital that is cheap, but it has many side effects. We aimed to compare the cost-effectiveness of topiramate versus phenobarbital in patients with febrile seizure in the south of Iran. MATERIALS &

methodsThis econometric cost-effectiveness and cost-utility study were conducted on 91 patients with febrile seizure to assess two strategies of oral drug therapy including phenobarbital and topiramate in 2016-2017. Of all, 51 patients were treated with phenobarbital and 40 patients received topiramate. We followed up the patients for six months, using a randomized and single-blinded approach. A decision tree model was used. The outcomes of the model included febrile seizure and utility. The study was conducted from the perspective of the community; therefore, direct and indirect costs were included in the study. Excel and Tree Age software (2011) were used to analyze the results.

resultsTopiramate was cheaper and more effective than phenobarbital. In patients in the phenobarbital and topiramate groups, the mean costs were $740 and $674 per PPP, utility scores were 0.72 and 0.82, and febrile seizure without side effects were 0.3 and 0.6, respectively. Moreover, one-way sensitivity analysis confirmed the robustness of the results of the study.

conclusionTopiramate in patients with febrile seizure is a fully cost-effective and cost-efficient strategy suggested as a better alternative for children with febrile seizure.

Indexed as

Cost-effectivenessCost-utilityFebrile seizurePhenobarbitalTopiramate

Identifiers

PMID31645871
PMCPMC6789090
OpenAlexW2977194097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.